![]() ![]() Researchers were independent from funders. ![]() This project was awarded the NACRe (French network for Nutrition And Cancer Research) Partnership Label. This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No 864219), the French National Cancer Institute (INCa_14059), the French Ministry of Health (arrêté 29.11.19) and the IdEx Université de Paris (ANR-18-IDEX-0001). EC was supported by a Doctoral Fellowship from Université Sorbonne Paris Nord to Galilée Doctoral School. CD was supported by a grant from the French National Cancer Institute (INCa, grant #2019-158). ![]() In accordance with existing regulations, no personal data will be accessible.įunding: The NutriNet-Santé study was supported by the following public institutions: Ministère de la Santé, Santé Publique France, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut national de recherche pour l’agriculture, l’alimentation et l’environnement (INRAE), Conservatoire National des Arts et Métiers (CNAM) and Université Sorbonne Paris Nord. If the collaboration is accepted, a data access agreement will be necessary and appropriate authorizations from the competent administrative authorities may be needed. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: Researchers from public institutions can submit a collaboration request including information on the institution and a brief description of the project to All requests will be reviewed by the steering committee of the NutriNet-Santé study. Received: NovemAccepted: FebruPublished: March 24, 2022Ĭopyright: © 2022 Debras et al. PLoS Med 19(3):Īcademic Editor: Wei Zheng, Vanderbilt University School of Medicine, UNITED STATES (2022) Artificial sweeteners and cancer risk: Results from the NutriNet-Santé population-based cohort study. Limitations of this study include potential selection bias, residual confounding, and reverse causality, though sensitivity analyses were performed to address these concerns.Ĭitation: Debras C, Chazelas E, Srour B, Druesne-Pecollo N, Esseddik Y, Szabo de Edelenyi F, et al. Higher risks were also observed for breast cancer ( n = 979 cases, HR = 1.22, P = 0.036, for aspartame) and obesity-related cancers ( n = 2,023 cases, HR = 1.13, P = 0.036, for total artificial sweeteners, and HR = 1.15, P = 0.026, for aspartame). In particular, aspartame (HR = 1.15, P = 0.002) and acesulfame-K (HR = 1.13, P = 0.007) were associated with increased cancer risk. Compared to non-consumers, higher consumers of total artificial sweeteners (i.e., above the median exposure in consumers) had higher risk of overall cancer ( n = 3,358 cases, hazard ratio = 1.13, P-trend = 0.002). Associations between sweeteners and cancer incidence were assessed by Cox proportional hazards models, adjusted for age, sex, education, physical activity, smoking, body mass index, height, weight gain during follow-up, diabetes, family history of cancer, number of 24-hour dietary records, and baseline intakes of energy, alcohol, sodium, saturated fatty acids, fibre, sugar, fruit and vegetables, whole-grain foods, and dairy products. Dietary intakes and consumption of sweeteners were obtained by repeated 24-hour dietary records including brand names of industrial products. Overall, 102,865 adults from the French population-based cohort NutriNet-Santé (2009–2021) were included (median follow-up time = 7.8 years).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |